Scholar Rock to Participate in Upcoming Investor Conferences

SRRK 10.31.2024

Full Press ReleaseSEC FilingsOur SRRK Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.14.2025 - 43rd Annual JP Morgan Healthcare Conference
  • 01.08.2025 - Scholar Rock Highlights 2025 Strategic Priorities

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

  • Truist Securities BioPharma Symposium:Scholar Rockis scheduled to participate in a panel presentation at3:25 p.m. ETonThursday, November 7inNew York City.
  • Jefferies London Healthcare Conference:Scholar Rockis scheduled to participate in a fireside chat at4:30 p.m. GMTonWednesday, November 20inLondon.
  • Piper Sandler 36th Annual Healthcare Conference:Scholar Rockis scheduled to participate in a fireside chat at1:30 p.m. ETonWednesday, December 4inNew York City.

A live webcast of the events may be accessed by visiting the Investors & Media section of theScholar Rockwebsite athttp://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company’s website for approximately 90 days.

AboutScholar Rock

Scholar Rockis a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade,Scholar Rockhas created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies,Scholar Rockworks every day to create new possibilities for patients. Learn more about our approach atScholarRock.comand follow @ScholarRock and on LinkedIn.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company websitewww.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs,Securities and Exchange Commissionfilings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock® is a registered trademark ofScholar Rock, Inc.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031493371/en/

Scholar Rock:InvestorsRushmie NofsingerScholar Rockrnofsinger@scholarrock.comir@scholarrock.com857-259-5573

MediaMolly MacLeodScholar Rockmmacleod@scholarrock.commedia@scholarrock.com802-579-599

Source:Scholar Rock

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com